Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 9/2018

01-09-2018 | Computer Applications

Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study

Authors: Zhi-Cheng Li, Hongmin Bai, Qiuchang Sun, Qihua Li, Lei Liu, Yan Zou, Yinsheng Chen, Chaofeng Liang, Hairong Zheng

Published in: European Radiology | Issue 9/2018

Login to get access

Abstract

Objectives

To build a reliable radiomics model from multiregional and multiparametric magnetic resonance imaging (MRI) for pretreatment prediction of O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status in glioblastoma multiforme (GBM).

Methods

In this retrospective multicentre study, 1,705 multiregional radiomics features were automatically extracted from multiparametric MRI. A radiomics model with a minimal set of all-relevant features and a radiomics model with univariately-predictive and non-redundant features were built for MGMT methylation prediction from a primary cohort (133 patients) and tested on an independent validation cohort (60 patients). Predictive models combing clinical factors were built and evaluated. Both radiomics models were assessed on subgroups stratified by clinical factors.

Results

The radiomics model with six all-relevant features allowed pretreatment prediction of MGMT methylation (AUC=0.88, accuracy=80 %), which significantly outperformed the model with eight univariately-predictive and non-redundant features (AUC=0.76, accuracy=70 %). Combing clinical factors with radiomics features did not benefit the prediction performance. The all-relevant model achieved significantly better performance in stratified analysis.

Conclusions

Radiomics model built from multiregional and multiparameter MRI may serve as a potential imaging biomarker for pretreatment prediction of MGMT methylation in GBM. The all-relevant features have the potential of offering better predictive power than the univariately-predictive and non-redundant features.

Key Points

• Multiregional and multiparametric MRI features reliably predicted MGMT methylation in multicentre cohorts.
• All-relevant imaging features predicted MGMT methylation better than univariately-predictive and non-redundant features.
• Combing clinical factors with radiomics features did not benefit the prediction performance.
Literature
1.
Ostrom QT, Gittleman H, Xu J, et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol 18:v1–v75
2.
Reardon DA, Wen PY (2015) Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol 12:69–70CrossRefPubMed
3.
Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39–51CrossRefPubMed
4.
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed
5.
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMed
6.
Sottoriva A, Spiteri I, Piccirillo SG et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci 110:4009–4014CrossRefPubMed
7.
Patel AP, Tirosh I, Trombetta JJ et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396–1401CrossRefPubMedPubMedCentral
8.
Dunn J, Baborie A, Alam F et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Brit J Cancer 101:124–131CrossRefPubMed
9.
Parker NR, Hudson AL, Khong P et al (2016) Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep 6:22477CrossRefPubMedPubMedCentral
10.
Drabycz S, Roldán G, De Robles P et al (2010) An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 49:1398–1405CrossRefPubMed
11.
Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am J Neuroradiol 33:1349–1355CrossRefPubMed
12.
Moon WJ, Choi JW, Roh HG, Lim SD, Koh YC (2012) Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology 54:555–563CrossRefPubMed
13.
Korfiatis P, Kline TL, Coufalova L et al (2016) MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med Phys 43:2835–2844CrossRefPubMedPubMedCentral
14.
Kanas VG, Zacharaki EI, Thomas GA, Zinn PO, Megalooikonomou V, Colen RR (2017) Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma. Comput Meth Prog Bio 140:249–257CrossRef
15.
16.
Lambin P, Leijenaar RT, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762CrossRefPubMed
17.
18.
Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by non-invasive imaging using a quantitative radiomics approach. Nat Comm 5
19.
Itakura H, Achrol AS, Mitchell LA et al (2015) Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Sci Transl Med 7:303ra138–303ra138CrossRefPubMedPubMedCentral
20.
Cui Y, Tha KK, Terasaka S et al (2015) Prognostic imaging biomarkers in glioblastoma: development and independent validation on the basis of multiregion and quantitative analysis of MR images. Radiology 278:546–553CrossRefPubMedPubMedCentral
21.
Li Q, Bai H, Chen Y et al (2017) A Fully-Automatic Multiparametric Radiomics Model: Towards Reproducible and Prognostic Imaging Signature for Prediction of Overall Survival in Glioblastoma Multiforme. Sci Rep 7:14331CrossRefPubMedPubMedCentral
22.
Kickingereder P, Götz M, Muschelli J et al (2016) Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin Cancer Res 22:5765–5771CrossRefPubMedPubMedCentral
23.
Cui Y, Ren S, Tha KK, Wu J, Shirato H, Li R (2017) Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma. Eur Radiol 27:3583–3592CrossRefPubMed
24.
Yoon RG, Kim HS, Paik W, Shim WH, Kim SJ, Kim JH (2017) Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation. Eur Radiol 27:255–266CrossRefPubMed
25.
Prasanna P, Patel J, Partovi S, Madabhushi A, Tiwari P (2017) Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings. Eur Radiol 27:4188–4197CrossRefPubMed
26.
Vartanian A, Singh SK, Agnihotri S et al (2014) GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro-oncology 16:1167–1175CrossRefPubMedPubMedCentral
27.
28.
Lemée JM, Clavreul A, Menei P (2015) Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. Neuro-oncology 17:1322–1332CrossRefPubMedPubMedCentral
29.
Havik AB, Brandal P, Honne H et al (2012) MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med 10:36CrossRefPubMedPubMedCentral
30.
Tustison NJ, Avants BB, Cook PA et al (2010) N4ITK: improved N3 bias correction. IEEE T Med Imaging 29:1310–1320CrossRef
31.
Lötjönen JM, Wolz R, Koikkalainen JR et al (2010) Fast and robust multi-atlas segmentation of brain magnetic resonance images. NeuroImage 49:2352–2365CrossRefPubMed
32.
Pereira S, Pinto A, Alves V, Silva CA (2016) Brain tumor segmentation using convolutional neural networks in MRI images. IEEE T Med Imaging 35:1240–1251CrossRef
33.
Menze BH, Jakab A, Bauer S et al (2015) The multimodal brain tumor image segmentation benchmark (BRATS). IEEE T Med Imaging 34:1993–2024CrossRef
34.
Abadi M, Agarwal A, Barham P et al (2016) Tensorflow: Large-scale machine learning on heterogeneous distributed systems. arXiv preprint:1603.04467
35.
Kursa MB, Rudnicki WR (2010) Feature selection with the Boruta package. J Stat Softw 36:1–13CrossRef
36.
37.
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics:837-845
38.
Nilsson R, Peña JM, Björkegren J, Tegnér J (2007) Consistent feature selection for pattern recognition in polynomial time. J Mach Learn Res 8:589–612
39.
40.
Guo P, Luo Y, Mai G et al (2014) Gene expression profile based classification models of psoriasis. Genomics 103:48–55CrossRefPubMed
41.
42.
Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non–small cell lung cancer: CT radiogenomic characterization. Radiology 272:568–576CrossRefPubMed
43.
Falconer DS, Mackay TFC (1996) Introduction to Genetics, Fourth edn. Addison Wesley Longman, Harlow, Essex, UK
44.
Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501:338–345CrossRefPubMed
45.
McCarthy N (2012) Tumour heterogeneity: Darwin's finches. Nat Rev Cancer 12:317–317PubMed
46.
Polyak K (2014) Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat Med 20:344–346CrossRefPubMed
47.
Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342–1350CrossRefPubMed
48.
Metadata
Title
Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study
Authors
Zhi-Cheng Li
Hongmin Bai
Qiuchang Sun
Qihua Li
Lei Liu
Yan Zou
Yinsheng Chen
Chaofeng Liang
Hairong Zheng
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 9/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-5302-1

Other articles of this Issue 9/2018

European Radiology 9/2018 Go to the issue

Oncology

Structured reporting adds clinical value in primary CT staging of diffuse large B-cell lymphoma

Hepatobiliary-Pancreas

CT diagnosis of gallbladder adenomyomatosis: importance of enhancing mucosal epithelium, the “cotton ball sign”

Head and Neck

Facial nerve tractography: A new tool for the detection of perineural spread in parotid cancers

Urogenital

T2-weighted balanced steady-state free procession MRI evaluated for diagnosing placental adhesion disorder in late pregnancy

Neuro

Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging

Breast

Contrast-enhanced cone-beam breast-CT (CBBCT): clinical performance compared to mammography and MRI